A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.
A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.
Inclusion Criteria:
Exclusion Criteria:
South Brisbane, Queensland 4101, Australia
Banja Luka, 88000, Bosnia and Herzegovina
Salvador, Bahia, Estado de Bahia 40170-380, Brazil
Sofia, 1757, Bulgaria
Medellin-Antioquia, Colombia
Bonn, 53127, Germany
Gütersloh, 33332, Germany
Hamburg, 20259, Germany
Oldenburg, 26121, Germany
Schwäbisch Hall, 74523, Germany
Würselen, 52146, Germany
Bari, Apulia 70124, Italy
Tricase - Le, Apulia 73039, Italy
Modena, Emilia-Romagna 41100, Italy
Aviano, Friuli Venezia Giulia 33081, Italy
Milan, Lombardy 20133, Italy
Milan, Lombardy 20162, Italy
Candiolo, Piedmont 10060, Italy
Novara, Piedmont 28100, Italy
Turin, Piedmont 10126, Italy
Turin, Piedmont 10126, Italy
Via S. Sofia 78, Sicily 95123, Italy
Torrette Di Ancona, The Marches 60020, Italy
Târgu Mureş, 540136, Romania
Jaén, 23007, Spain
Malmö, 205 02, Sweden
Zurich, 8091, Switzerland